ALK and non-small cell lung carcinoma: In the past decade, conventional treatments, such as resection, platinum-based chemotherapy, radiotherapy, and targeted therapy, have significantly improved the prognosis of non-small-cell lung cancer (NSCLC), which can have oncogenic driver mutations, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations (2).